XHKG1931
Market cap339mUSD
Dec 24, Last price
1.62HKD
1Q
-18.18%
IPO
-47.23%
Name
Ivd Medical Holding Ltd
Chart & Performance
P/E
10.39
P/S
0.80
EPS
0.15
Div Yield, %
2.90%
Shrs. gr., 5y
16.96%
Rev. gr., 5y
49.49%
Revenues
3.09b
+12.35%
Net income
238m
+13.41%
CFO
292m
+17.12%
Dividend
Jul 15, 20240.06209 HKD/sh
Earnings
May 16, 2025
Profile
IVD Medical Holding Limited, an investment holding company, distributes In vitro diagnostic (IVD) products in Mainland China and internationally. The company operates through three segments: Distribution Business, Maintenance Services, and Self-branded Products Business. It offers IVD analysers, reagents, and other consumables for various IVD testing categories, including hematology and body fluid, immunoassay, clinical chemistry, molecular, microbiology, and point-of-care testing. The company also provides haemostasis products; solution services to the clinical laboratories of hospitals; and maintenance services, such as maintenance and repair, installation, and end customer training services. In addition, it researches, develops, manufactures, and sells IVD analyzers and reagents under the IVD brand. The company offers its products to hospitals and healthcare institutions, logistics providers, and distributors. IVD Medical Holding Limited was founded in 1993 and is headquartered in Shanghai, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 3,088,387 12.35% | 2,748,809 0.66% | 2,730,670 12.46% | |||||
Cost of revenue | 2,721,644 | 2,418,043 | 2,478,094 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 366,743 | 330,766 | 252,576 | |||||
NOPBT Margin | 11.87% | 12.03% | 9.25% | |||||
Operating Taxes | 102,203 | 88,259 | 106,190 | |||||
Tax Rate | 27.87% | 26.68% | 42.04% | |||||
NOPAT | 264,540 | 242,507 | 146,386 | |||||
Net income | 238,163 13.41% | 209,999 20.31% | 174,541 9.97% | |||||
Dividends | (76,346) | (52,963) | (50,439) | |||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 845 | |||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 331,032 | 329,497 | 427,653 | |||||
Long-term debt | 37,714 | 32,990 | 30,342 | |||||
Deferred revenue | (12,566) | (11,498) | ||||||
Other long-term liabilities | 186,752 | 12,566 | 11,498 | |||||
Net debt | (940,164) | (794,651) | (488,163) | |||||
| Cash flow | ||||||||
Cash from operating activities | 292,424 | 249,671 | 163,108 | |||||
CAPEX | (40,508) | (34,285) | (25,232) | |||||
Cash from investing activities | (77,585) | 60,536 | (27,884) | |||||
Cash from financing activities | (19,453) | (191,287) | (66,289) | |||||
FCF | 157,655 | 375,753 | 92,812 | |||||
| Balance | ||||||||
Cash | 1,240,334 | 1,041,853 | 841,785 | |||||
Long term investments | 68,576 | 115,285 | 104,373 | |||||
Excess cash | 1,154,491 | 1,019,698 | 809,624 | |||||
Stockholders' equity | 1,161,594 | 824,664 | 577,679 | |||||
Invested Capital | 2,762,471 | 2,632,972 | 2,819,248 | |||||
ROIC | 9.81% | 8.90% | 5.18% | |||||
ROCE | 9.36% | 9.04% | 7.01% | |||||
| EV | ||||||||
Common stock shares outstanding | 1,351,885 | 1,354,969 | 1,349,272 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 404,302 | 366,055 | 291,382 | |||||
EV/EBITDA | ||||||||
Interest | 21,040 | 30,580 | 20,422 | |||||
Interest/NOPBT | 5.74% | 9.25% | 8.09% | |||||